VYNE Therapeutics Inc.

Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements

During the three months ended March 31, 2026, none of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended)adopted orterminated any contracts, instructions or written plans for the purchase or sale of our securities.

Combined Employment Agreement – Tyler Zeronda

On May 14, 2026, Yarrow Bioscience, Inc. entered into an employment agreement (the “Employment Agreement”) with our Chief Financial Officer, Tyler Zeronda, in connection with the Merger. Pursuant to the Employment Agreement, Mr. Zeronda was offered a position as Chief Financial Officer of the Combined Company contingent upon the completion of the Merger and will receive an annualized base salary of $480,000. Mr. Zeronda is also eligible to receive an annual target bonus of 40% of his annual base salary, subject to the achievement of corporate performance targets established annually by the Combined Company. In addition, pursuant to the Employment Agreement, Mr. Zeronda will be granted stock options to purchase shares of the Combined Company's common stock and pre-funded warrants representing approximately 0.65% of the Combined Company's outstanding common stock and pre-funded warrants as of the closing of the Merger, subject to the terms and conditions set forth in the Employment Agreement.

In the event of a termination of his employment without Cause or if he resigns for Good Reason (each, as defined in the Employment Agreement), subject to Mr. Zeronda’s execution of a release of claims, Mr. Zeronda will receive (i) a severance payment equal to nine months of his base salary then in effect, in accordance with the Combined Company’s regular payroll practices, and (ii) payment of COBRA premiums for healthcare plan continuation at active employee rates for nine months following the date of termination, provided that the Combined Company’s obligation under clause (ii) shall terminate on the earlier of (x) the date on which he enrolls in a group health plan offered by another employer and (y) the date on which he is no longer eligible for continuation coverage under COBRA.

In addition, if Mr. Zeronda’s employment is terminated by the Combined Company without Cause or if he terminates his employment with Good Reason within the 12 month period after a Change of Control (as defined in the Combined Company’s 2026 Stock Incentive Plan), he will be entitled to receive a change of control payment equal to (i) 12 months of his current base salary plus his target bonus, (ii) his pro rata target bonus for the year of termination, and (iii) payment of COBRA premiums for healthcare plan continuation at active employee rates for 12 months following the date of termination, provided that the Combined Company’s obligation under clause (iii) shall terminate on the earlier of (x) the date on which he enrolls in a group health plan offered by another employer and (y) the date on which he is no longer eligible for continuation coverage under COBRA. In addition, in the event of such a termination, all of Mr. Zeronda’s unvested equity awards will be accelerated and become fully vested.

The foregoing description is not complete and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.

Transaction Bonus – Tyler Zeronda

In recognition of Mr. Zeronda’s contributions to VYNE and the benefit of Mr. Zeronda continuing as the Combined Company’s Chief Financial Officer following the Merger, on May 14, 2026, VYNE’s Compensation Committee approved a one-time transaction bonus for Mr. Zeronda equal to his target annual cash bonus of $178,061. The Transaction Bonus will be paid upon the closing of the Merger, subject to Mr. Zeronda remaining in continuous service with VYNE through the closing.